These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 15330171)
1. Pre-clinical immunogenicity and anti-tumour efficacy of a deleted recombinant human papillomavirus type 16 E7 protein. Hallez S; Brulet JM; Vandooren C; Maudoux F; Thomas S; Heinderickx M; Bollen A; Wattiez R; Jacquet A Anticancer Res; 2004; 24(4):2265-75. PubMed ID: 15330171 [TBL] [Abstract][Full Text] [Related]
2. Human papillomavirus type 16 E7 peptide(38-61) linked with an immunoglobulin G fragment provides protective immunity in mice. Qin Y; Wang XH; Cui HL; Cheung YK; Hu MH; Zhu SG; Xie Y Gynecol Oncol; 2005 Feb; 96(2):475-83. PubMed ID: 15661238 [TBL] [Abstract][Full Text] [Related]
3. Fusion of a tumour-associated antigen to HIV-1 Tat improves protein-based immunotherapy of cancer. Giannouli C; Brulet JM; Gesché F; Rappaport J; Burny A; Leo O; Hallez S Anticancer Res; 2003; 23(4):3523-31. PubMed ID: 12926102 [TBL] [Abstract][Full Text] [Related]
4. Chemically synthesized protein as tumour-specific vaccine: immunogenicity and efficacy of synthetic HPV16 E7 in the TC-1 mouse tumour model. Welters MJ; Filippov DV; van den Eeden SJ; Franken KL; Nouta J; Valentijn AR; van der Marel GA; Overkleeft HS; Lipford G; Offringa R; Melief CJ; van Boom JH; van der Burg SH; Drijfhout JW Vaccine; 2004 Dec; 23(3):305-11. PubMed ID: 15530672 [TBL] [Abstract][Full Text] [Related]
5. Both E7 and CpG-oligodeoxynucleotide are required for protective immunity against challenge with human papillomavirus 16 (E6/E7) immortalized tumor cells: involvement of CD4+ and CD8+ T cells in protection. Kim TY; Myoung HJ; Kim JH; Moon IS; Kim TG; Ahn WS; Sin JI Cancer Res; 2002 Dec; 62(24):7234-40. PubMed ID: 12499264 [TBL] [Abstract][Full Text] [Related]
6. Eradication of established tumors by vaccination with recombinant Bordetella pertussis adenylate cyclase carrying the human papillomavirus 16 E7 oncoprotein. Préville X; Ladant D; Timmerman B; Leclerc C Cancer Res; 2005 Jan; 65(2):641-9. PubMed ID: 15695409 [TBL] [Abstract][Full Text] [Related]
8. An improved rearranged Human Papillomavirus Type 16 E7 DNA vaccine candidate (HPV-16 E7SH) induces an E7 wildtype-specific T cell response. Ohlschläger P; Pes M; Osen W; Dürst M; Schneider A; Gissmann L; Kaufmann AM Vaccine; 2006 Apr; 24(15):2880-93. PubMed ID: 16472545 [TBL] [Abstract][Full Text] [Related]
9. HPV16E7 tumor antigen modified by KDEL sequence induce specific cytotoxic T lymphocytes-dependent antitumor immunity. Yin R; Zheng W; Hao F; Yang XC; Zhong BY; Li QJ J Dermatol Sci; 2009 Aug; 55(2):116-22. PubMed ID: 19500947 [TBL] [Abstract][Full Text] [Related]
10. [Expression of the human papillomavirus type 16L/E7 fusion protein in E. coli and observation of its immunogenicity in mice]. Tian HW; Ye ZM; Lu ZH; Jao R; Bian T; Zhao L; Ruan L Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2006 Jun; 20(2):33-7. PubMed ID: 16816859 [TBL] [Abstract][Full Text] [Related]
11. Plant-derived human papillomavirus 16 E7 oncoprotein induces immune response and specific tumor protection. Franconi R; Di Bonito P; Dibello F; Accardi L; Muller A; Cirilli A; Simeone P; Donà MG; Venuti A; Giorgi C Cancer Res; 2002 Jul; 62(13):3654-8. PubMed ID: 12097270 [TBL] [Abstract][Full Text] [Related]
12. Modified HPV16 E7 Genes as DNA Vaccine against E7-Containing Oncogenic Cells. Smahel M; Síma P; Ludvíková V; Vonka V Virology; 2001 Mar; 281(2):231-8. PubMed ID: 11277695 [TBL] [Abstract][Full Text] [Related]
13. Modified HPV16 E7/HSP70 DNA vaccine with high safety and enhanced cellular immunity represses murine lung metastatic tumors with downregulated expression of MHC class I molecules. Li H; Ou X; Xiong J Gynecol Oncol; 2007 Mar; 104(3):564-71. PubMed ID: 17081598 [TBL] [Abstract][Full Text] [Related]
14. Exploiting the plant secretory pathway to improve the anticancer activity of a plant-derived HPV16 E7 vaccine. Franconi R; Massa S; Illiano E; Mullar A; Cirilli A; Accardi L; Di Bonito P; Giorgi C; Venuti A Int J Immunopathol Pharmacol; 2006; 19(1):187-97. PubMed ID: 16569357 [TBL] [Abstract][Full Text] [Related]
15. A DNA vaccine constructed with human papillomavirus type 16 (HPV16) E7 and E6 genes induced specific immune responses. Yan Q; Cheung YK; Cheng SC; Wang XH; Shi M; Hu MH; Yong X Gynecol Oncol; 2007 Jan; 104(1):199-206. PubMed ID: 17049969 [TBL] [Abstract][Full Text] [Related]
16. Combined immunization with fusion genes of mutated E7 gene of human papillomavirus type 16 did not enhance antitumor effect. Pokorná D; Macková J; Dusková M; Rittich S; Ludvíková V; Smahel M J Gene Med; 2005 Jun; 7(6):696-707. PubMed ID: 15712328 [TBL] [Abstract][Full Text] [Related]
17. [Immunogenicity of mutant and wild HPV16 DNA vaccines]. Zuo YG; Wang JB; Jin HZ; Yue-hua L Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2004 Oct; 26(5):554-7. PubMed ID: 15562771 [TBL] [Abstract][Full Text] [Related]
18. Enhancement of vaccinia vaccine potency by linkage of tumor antigen gene to gene encoding calreticulin. Hsieh CJ; Kim TW; Hung CF; Juang J; Moniz M; Boyd DA; He L; Chen PJ; Chen CH; Wu TC Vaccine; 2004 Sep; 22(29-30):3993-4001. PubMed ID: 15364449 [TBL] [Abstract][Full Text] [Related]
19. DNA vaccines against HPV-16 E7-expressing tumour cells. De Marco F; Hallez S; Brulet JM; Gesché F; Marzano P; Flamini S; Marcante ML; Venuti A Anticancer Res; 2003; 23(2B):1449-54. PubMed ID: 12820408 [TBL] [Abstract][Full Text] [Related]
20. Eradication of established tumors by vaccination with Venezuelan equine encephalitis virus replicon particles delivering human papillomavirus 16 E7 RNA. Velders MP; McElhiney S; Cassetti MC; Eiben GL; Higgins T; Kovacs GR; Elmishad AG; Kast WM; Smith LR Cancer Res; 2001 Nov; 61(21):7861-7. PubMed ID: 11691804 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]